Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2003-03-17
2010-10-12
Lucas, Zachariah (Department: 1648)
Chemistry: molecular biology and microbiology
Vector, per se
Reexamination Certificate
active
07811812
ABSTRACT:
Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.
REFERENCES:
patent: 5026686 (1991-06-01), Schlesinger et al.
patent: 5091309 (1992-02-01), Schlesinger et al.
patent: 5185440 (1993-02-01), Davis et al.
patent: 5217879 (1993-06-01), Huang et al.
patent: 5466788 (1995-11-01), Ahlquist et al.
patent: 5505947 (1996-04-01), Johnston et al.
patent: 5532154 (1996-07-01), Brown
patent: 5578475 (1996-11-01), Jessee
patent: 5591579 (1997-01-01), Olivo et al.
patent: 5614404 (1997-03-01), Mazzara et al.
patent: 5643576 (1997-07-01), Johnston et al.
patent: 5691177 (1997-11-01), Guber et al.
patent: 5739026 (1998-04-01), Garoff et al.
patent: 5766602 (1998-06-01), Xiong et al.
patent: 5789245 (1998-08-01), Dubensky, Jr. et al.
patent: 5792462 (1998-08-01), Johnston et al.
patent: 5797870 (1998-08-01), March et al.
patent: 5811407 (1998-09-01), Johnston et al.
patent: 5814482 (1998-09-01), Dubensky et al.
patent: 5843712 (1998-12-01), Levine
patent: 5843723 (1998-12-01), Dubensky, Jr. et al.
patent: 5851757 (1998-12-01), Olivo et al.
patent: 6015686 (2000-01-01), Dubensky et al.
patent: 6391632 (2002-05-01), Dubensky, Jr. et al.
patent: 6426196 (2002-07-01), Dubensky, Jr. et al.
patent: 6451592 (2002-09-01), Dubensky et al.
patent: 6458560 (2002-10-01), Dubensky, Jr. et al.
patent: 6465634 (2002-10-01), Dubensky, Jr. et al.
patent: 6592874 (2003-07-01), Schlesinger et al.
patent: 2200651 (1988-08-01), None
patent: WO 88/00472 (1988-01-01), None
patent: WO8910973 (1989-11-01), None
patent: WO9102805 (1991-03-01), None
patent: WO9206693 (1992-04-01), None
patent: WO 92/10578 (1992-06-01), None
patent: WO 94/17813 (1994-08-01), None
patent: WO9426912 (1994-11-01), None
patent: WO 95/07994 (1995-03-01), None
patent: WO 95/17525 (1995-06-01), None
patent: WO 95/19990 (1995-07-01), None
patent: WO 95/25788 (1995-09-01), None
patent: WO 95/27044 (1995-10-01), None
patent: WO 95/27069 (1995-10-01), None
patent: WO 95/31565 (1995-11-01), None
patent: WO 95/32733 (1995-12-01), None
patent: WO 96/17072 (1996-06-01), None
patent: WO 96/37616 (1996-11-01), None
patent: WO 96/39830 (1996-12-01), None
patent: WO9716169 (1997-05-01), None
patent: WO9724447 (1997-07-01), None
patent: WO9730155 (1997-08-01), None
patent: WO 97/38087 (1997-10-01), None
patent: WO9744446 (1997-11-01), None
patent: WO9813511 (1998-04-01), None
patent: WO9815636 (1998-04-01), None
patent: WO9826084 (1998-06-01), None
patent: WO9836779 (1998-08-01), None
patent: WO9853077 (1998-11-01), None
patent: WO9909192 (1999-02-01), None
patent: WO9911808 (1999-03-01), None
patent: WO9915641 (1999-04-01), None
patent: WO9918226 (1999-04-01), None
patent: WO9925858 (1999-05-01), None
patent: WO9925859 (1999-05-01), None
patent: WO9930734 (1999-06-01), None
Strass et al., Budding of alphaviruses, Trends in Microbiology, 1995, 3(9):346-350.
Baumann et al., “Interleukin-1I regulates the hepatic expression of the same plasma protein genes as interleukin-6,” J. Biological Chemistry 266:20424-20427, 1991.
Beauchemin et al., “Isolation and characterization of full-length functional cDNA clones for human carcinoembryonic antigen,” Molecular and Cellular Biology 7(9):3221-3230,1987.
Beier et al., “Association of human class 1 MHC alleles with the adenovirus E3/19K protein,” J. Immunology 152:3862-3872, 1994.
Berglund et al., “Alphaviruses as vectors for gene delivery,” Trends in Biotechnology 14:130-134, 1996.
Berglund et al., “Semliki forest virus expression system: production of conditionally infectious recombinant particles,” Bio/Techmology 11:916-920, 1993.
Boyer et al., “Infectious transcripts and cDNA clones of RNA viruses,” Virology 198:415-426, 1994.
Bredenbeek et al., “Animal RNA virus expression systems,” Seminars in Virology 3:297-310, 1992.
Browne et al., “A complex between the MHC class 1 homologue encoded by human cytomegalovirus and β2microglobulin,” Nature 347:770-772, 1990.
Culver et al., “Gene therapy for cancer,” TIG 10(5):174-178, 1994.
Davis et al., “In vitro synthesis of infectious Venezuelan equine encephalitis virus RNA from a cDNA clone: analysis of a viable deletion mutant,” Virology 171:189-204, 1989.
Davis et al., “Protection against influenza in mice by vaccination with a Venezuelan equine encephalitis virus vector expressing the HA protein,” J. Cell Biochem. Suppl. 19A(10): abstract No. J2-308, 1995.
Driver et al., “Layered amplification of gene expression with a DNA gene delivery system,” Annals of New York Academy of Sciences 772(1):261-264, 1995.
Dryga et al., “Identification of mutations in a sindbis virus bariant able to establish persistent infection in BHK cells: the importance of a mutation in the nsP2 gene,” Virology 228:74-83, 1997.
Dubensky et al., “Polynucleotide based gene transfer vector derived from an alphavirus,” J. Cellular Biochemistry Supplement 0(21 A):406, abstract No. C6-413, 1995.
Dubensky et al., “Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene transfer,” J. Virology 70(1):508-519, 1996.
Dubuisson et al., “Sindbis virus attachment, isolation and characterization of mutants with impaired binding to bertebrate cells,” J. Virology 67(6):3363-3374, 1993.
Frolov et al., “Comparison of the effects of Sindbis and Sindbis virus replicons on host cell protein synthesis and cytopathogenicity in BHK cells,” J. Virology 68(3):1721-1727, 1994.
Gassman et al., “Analysis of the Borrelia Burgdorferi GeHo fla gene and antigenic characterization of its gene product,” J. Bacteriology 173(4):1452-1459, 1991.
Geigenmüller-Gnirke et al., “Complementation between Sindbis viral RNAs produces infectious particles with a bipartite genome,” Proc. Natl. Acad. Sci. USA 88:3253-3257, 1991.
Grakoui et al., “A cis-acting mutation in the Sindbis virus junction region which affects subgenomic RNA synthesis,” J. Virology 63(12):5216-5227,1989.
Hahn et al., “Infectious Sindbis virus transient expression vectors for studying antigen processing and presentation,” Proc. Natl. Acad. Scil USA 89:2679-2683, 1992.
Hertz et al., “Utilization of heterologous alphairus junction sequences as promoters by Sindbis virus,” J. Virology 66(2):957-964, 1992.
Herweijer et al., “A plasmid-based self-amplifying Sindbis virus vector,” Human Gene Therapy 6:1161-1167, 1995.
Hodgson, “Advances in vector systems for gene therapy,” Exp. Opin. Ther. Patents 5(5):459-468, 1995.
Huang et al., “RNA viruses as gene expression vectors,” Virus Genes 3(1):85-91, 1989.
Huang et al., “Liposomal gene delivery: a complex package,” Nature Biotechnology 15:620-621, 1997.
Johanning et al., “A Sindbis virus mRNA polynucleotide vector achieves prolonged and high level heterologous gene expression in vivo,” Nucleic Acids Research 23(9):1495-1501, 1995.
Kuhn et al., “Infectious RNA transcripts from ross river virus cDNA clones and the construction and characterization of defined chimeras with Sindbis virus,” Virology 182:430-441, 1991.
Kuo et al., “An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis,” Science 244:362-364, 1989.
Lemm et al., “Mutations which alter the level
Belli Barbara A.
Drvga Sergey A.
Dubensky, Jr. Thomas W.
Frolov Ilya
Polo John M.
Bautista Regina
Kinsey White Nicole
Lee Helen
Lucas Zachariah
Novartis Vaccines & Diagnostics, Inc.
LandOfFree
Recombinant alphavirus-based vectors with reduced inhibition... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant alphavirus-based vectors with reduced inhibition..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant alphavirus-based vectors with reduced inhibition... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4212549